false
The Precision Blog
100% sourced from leading minds on the front lines of research
Recent and Featured Posts
View all articles-
Read Singapore Clinical Trials: A Fast, Efficient Hub for APAC Research
-
Read The Immune System's Secret Language: Unlocking Cellular Communication The Immune System's Secret Language: Unlocking Cellular Communication
Read Case Study: Biomarker-Driven Enrollment Using Notch Mutation Targeting Case Study: Biomarker-Driven Enrollment Using Notch Mutation Targeting
Read Empowering Clinical Operations with Enhanced Biospecimen Lifecycle Management Empowering Clinical Operations with Enhanced Biospecimen Lifecycle Management
-
-
Read: Singapore Clinical Trials: A Fast, Efficient Hub for APAC Research 
Singapore Clinical Trials: A Fast, Efficient Hub for APAC Research
has not third author: true, (SizeLimitingPyMap: {main={hs_id=197935898186, hs_child_table_id=0, hs_updated_at=1761062728726, hs_published_at=1761062733198, description=Hardik Badani is a seasoned clinical research professional with a proven track record in managing complex, multi-regional clinical trials across North America, Europe, Asia-Pacific, and Africa. Based in Singapore, Hardik brings over a decade of experience in clinical operations, portfolio oversight, and project finance. He is a certified Project Management Professional (PMP) and was recognized with the Bronze award at the 2020 PharmaTimes International Clinical Researcher of the Year competition. Hardik’s expertise spans the full spectrum of clinical trial delivery—from startup through closeout—with a strong command of clinical systems including CTMS and EDC platforms. His leadership style emphasizes collaboration, operational excellence, and a deep commitment to advancing global health through precision-driven research., avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Hardik%20Badani.png',altText='Hardik Badani',fileId=197937156662}, lastname=Badani, hs_initial_published_at=1761062733198, hs_created_by_user_id=26433386, hs_created_at=1761062663685, hs_is_edited=false, hs_deleted_at=0, name=Hardik, job=Principal Clinical Trial Manager, slug=hardik-badani, hs_updated_by_user_id=26433386}, second={hs_id=167906611101, hs_child_table_id=0, hs_updated_at=1743507158804, hs_published_at=1761062733198, description=Helen brings over 30 years of experience in multinational healthcare, biotech, and pharmaceutical industries, including work with Medical Research Institutes and CROs. She specializes in leading clinical research, drug and device development, and fostering innovative research collaborations. Based in Sydney, Australia, Helen has a strong track record of delivering clinical trials across the APAC region., avatar=Image{width=600,height=700,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Helene-Ormandy.png',altText='Helene-Ormandy',fileId=168387434767}, lastname=Ormandy, PhD, hs_initial_published_at=1716212950394, hs_created_by_user_id=2737751, hs_created_at=1716212897654, hs_is_edited=false, hs_deleted_at=0, name=Helen, job=Senior Director, Clinical Operations, slug=helen-ormandy, hs_updated_by_user_id=26433386}, third={}}) -
-
Read: Case Study: Biomarker-Driven Enrollment Using Notch Mutation Targeting 
Case Study: Biomarker-Driven Enrollment Using Notch Mutation Targeting
has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1754641451547, hs_published_at=1761062733198, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins.png',altText='Alexis-Hobbins',fileId=194096322982}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=26433386}, second={}, third={}}) -
-
Read: Case Study: Global Phase 1-2 TCR Therapy in Advanced Solid Tumors 
Case Study: Global Phase 1-2 TCR Therapy in Advanced Solid Tumors
has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1754641451547, hs_published_at=1761062733198, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins.png',altText='Alexis-Hobbins',fileId=194096322982}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=26433386}, second={}, third={}}) -
-
-
-
Read: The Immune System's Secret Language: Unlocking Cellular Communication 
The Immune System's Secret Language: Unlocking Cellular Communication
has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778858, hs_child_table_id=0, hs_updated_at=1754641583843, hs_published_at=1761062733198, description=Rob Maiale is a marketing strategist and creative technologist with 17 years of experience turning complex ideas into growth. He currently leads content strategy, where he transforms insights from Precision experts into market-shaping narratives that drive the advancement of next-generation therapies. Rob’s career spans journalism, advertising, and brand storytelling, with a through-line of making the meaningful memorable. His work blends creative strategy with emerging AI tools to help Precision stay ahead of the curve—and above the noise., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/rob.png',altText='rob',fileId=194099000843}, linkedin=https://www.linkedin.com/in/rob-maiale/, hs_name=, hs_path=, lastname=Maiale, hs_initial_published_at=1758208027822, hs_created_at=1709645745089, hs_is_edited=false, hs_deleted_at=0, name=Rob, position=Associate Director, Digital Content & Inbound Marketing, job=, slug=rob-maiale, email=, hs_updated_by_user_id=26433386}, second={}, third={}}) -
-
Read: How AI & Biomarkers Are Reshaping the Next Frontier in Drug Development 
How AI & Biomarkers Are Reshaping the Next Frontier in Drug Development
has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778858, hs_child_table_id=0, hs_updated_at=1754641583843, hs_published_at=1761062733198, description=Rob Maiale is a marketing strategist and creative technologist with 17 years of experience turning complex ideas into growth. He currently leads content strategy, where he transforms insights from Precision experts into market-shaping narratives that drive the advancement of next-generation therapies. Rob’s career spans journalism, advertising, and brand storytelling, with a through-line of making the meaningful memorable. His work blends creative strategy with emerging AI tools to help Precision stay ahead of the curve—and above the noise., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/rob.png',altText='rob',fileId=194099000843}, linkedin=https://www.linkedin.com/in/rob-maiale/, hs_name=, hs_path=, lastname=Maiale, hs_initial_published_at=1758208027822, hs_created_at=1709645745089, hs_is_edited=false, hs_deleted_at=0, name=Rob, position=Associate Director, Digital Content & Inbound Marketing, job=, slug=rob-maiale, email=, hs_updated_by_user_id=26433386}, second={}, third={}}) -
-
Read: Mining for Gold? Prospecting Biospecimen Collections to Power Precision Medicine 
Mining for Gold? Prospecting Biospecimen Collections to Power Precision Medicine
has not third author: true, (SizeLimitingPyMap: {main={hs_id=193399854592, hs_child_table_id=0, hs_updated_at=1754641147525, hs_published_at=1761062733198, description=George Rogers is a scientific storyteller with over two decades of experience translating complex biology into content that connects. At Precision for Medicine, he facilitates scientific content development, crafting articles, case studies and presentations that spotlight the company’s integrated support for sponsors, from biomarker discovery and translational science to clinical trial execution and regulatory guidance. George’s background in cell analysis and drug development informs his ability to turn complex science into clear, compelling narratives that support business development and drive engagement across the life sciences landscape., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Geaorge-W-Rogers%2c-PhD-1.png',altText='Geaorge-W-Rogers,-PhD-1',fileId=194123711872}, lastname=Rogers, PhD, hs_initial_published_at=1753469768389, hs_created_by_user_id=26433386, hs_created_at=1753469702664, hs_is_edited=false, hs_deleted_at=0, name=George, job=Senior Manager, Scientific Content, slug=george-rogers-phd, hs_updated_by_user_id=26433386}, second={}, third={}}) -
-
All articles
-
Read: Study Start-Up vs Site Start-Up in Clinical Research: Understanding Modern Trial Dynamics 
Study Start-Up vs Site Start-Up in Clinical Research: Understanding Modern Trial Dynamics
has not third author: true, (SizeLimitingPyMap: {main={hs_id=169565849890, hs_child_table_id=0, hs_updated_at=1754641407932, hs_published_at=1761062733198, avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Barbara-Kathage-1.png',altText='Barbara-Kathage-1',fileId=194126030113}, lastname=Kathage, hs_initial_published_at=1718988967067, hs_created_by_user_id=26433386, hs_created_at=1717603865843, hs_is_edited=false, hs_deleted_at=0, name=Barbara, job=Vice President, Site Start Up, slug=barbara-kathage, hs_updated_by_user_id=26433386}, second={}, third={}}) -
-
Read: Clinical Trial Site Selection: Key Challenges & Solutions for Phase 3 Success .jpg?width=396&height=224&name=7%20Common%20Phase%203%20Clinical%20Trial%20Site%20Selection%20Challenges%20(And%20How%20to%20Solve%20Them).jpg)
Clinical Trial Site Selection: Key Challenges & Solutions for Phase 3 Success
has not third author: true, (SizeLimitingPyMap: {main={hs_id=169565849890, hs_child_table_id=0, hs_updated_at=1754641407932, hs_published_at=1761062733198, avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Barbara-Kathage-1.png',altText='Barbara-Kathage-1',fileId=194126030113}, lastname=Kathage, hs_initial_published_at=1718988967067, hs_created_by_user_id=26433386, hs_created_at=1717603865843, hs_is_edited=false, hs_deleted_at=0, name=Barbara, job=Vice President, Site Start Up, slug=barbara-kathage, hs_updated_by_user_id=26433386}, second={}, third={}}) -
-
Read: Navigating Site Activation Strategy Under the EU Clinical Trials Regulation 
Navigating Site Activation Strategy Under the EU Clinical Trials Regulation
has not third author: true, (SizeLimitingPyMap: {main={hs_id=169565849890, hs_child_table_id=0, hs_updated_at=1754641407932, hs_published_at=1761062733198, avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Barbara-Kathage-1.png',altText='Barbara-Kathage-1',fileId=194126030113}, lastname=Kathage, hs_initial_published_at=1718988967067, hs_created_by_user_id=26433386, hs_created_at=1717603865843, hs_is_edited=false, hs_deleted_at=0, name=Barbara, job=Vice President, Site Start Up, slug=barbara-kathage, hs_updated_by_user_id=26433386}, second={hs_id=159488778852, hs_child_table_id=0, hs_updated_at=1716212815818, hs_published_at=1761062733198, description=Chris Ingram, BSc (Hons) is Head of Regulatory Consultancy (Europe) for Precision for Medicine. Chris received his BSc(Hons) in immunology and pharmacology from the University of Strathclyde and has since spent over 21 years working in regulatory affairs with a focus on clinical development. Chris’ regulatory expertise covers clinical development across all phases, regulatory strategy, marketing authorisations, scientific advice, orphan drug designation and paediatric investigation plans across a wide variety of therapeutic areas, including but not limited to, oncology, CNS, metabolic, endocrinology, analgesia and cardiovascular., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Chris%20Ingram.webp',altText='Chris Ingram',fileId=165893120791}, linkedin=https://www.linkedin.com/in/chris-ingram-0255b216, hs_name=, hs_path=, lastname=Ingram, hs_initial_published_at=1758208027822, hs_created_at=1709645745083, hs_is_edited=false, hs_deleted_at=0, name=Chris, job=Executive Director, Regulatory Affairs, Europe, slug=chris-ingram, email=, hs_updated_by_user_id=26433386}, third={}}) -
You've reach the end